In a retrospective study of 123 patients with advanced CRC who were treated with bevacizumab combined with chemotherapy, the RFS and OS rates of CRC patients with low tumor interstitial CD68+ TAMs were significantly higher. This evidence concerns the gene CD68 and neoplasm.